Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
View/ Open
Date
2024-02-29ICR Author
Author
Chisholm, J
Mandeville, H
Adams, M
Minard-Collin, V
Rogers, T
Kelsey, A
Shipley, J
van Rijn, RR
de Vries, I
van Ewijk, R
de Keizer, B
Gatz, SA
Casanova, M
Hjalgrim, LL
Firth, C
Wheatley, K
Kearns, P
Liu, W
Kirkham, A
Rees, H
Bisogno, G
Wasti, A
Wakeling, S
Heenen, D
Tweddle, DA
Merks, JHM
Jenney, M
Type
Journal Article
Metadata
Show full item recordAbstract
The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.
Collections
Language
eng
Date accepted
2024-02-26
License start date
2024-02-29
Citation
Cancers, 2024, 16 (5), pp. 998 - 998
Publisher
MDPI